Brief Summary:
« A phase I-II study in patients with mutated MPN by vaccinating with PD-L1 and Aginase1 peptides with Montanide ISA-51 as adjuvant, to monitor the immunological response to vaccination and subsequently safety, toxicity and clinical effect »
Thank you for sharing this. So it started in July 19 in Denmark. The first year results may be available? I thought the conditions for being accepted were fascinating.
Thank you- exciting, couldn’t really work out the vaccination goal.
The goal of vaccination ? A cure eventually!
« We envisage a new and bright future with many more patients with MPNs obtaining MRD on the above therapies. From this stage-and even before-vaccination strategies may open a new horizon with cure being the goal for some patients »
Very interesting. The last thing I saw on a vaccine based treatment was for the CALR mutation, which apparently the immune system can be trained to recognize. The challenge with JAK2 is that the immune system cannot distinguish mutated hemopoietic stem cells from the wild-type (normal) HSCs. WIll be very interesting to see what comes from the research.
Advice for Patients with Myeloproliferative Neoplasms - 19th March 2020
COVID-19 & MYELOPROLIFERATIVE NEOPLASMS: FAQs & UPDATES from ASH_30.03.20
New! advances in the role of JAK2 V617F mutation in myeloproliferative neoplasms (MPN)New advances in the role of JAK2 V617F mutation in myeloproliferative neoplasms
Really??: Pruritus May Mark Severe Symptomology in Myeloproliferative Neoplasms"- From "Hematology Advisor"- Some surprising findings...
